Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice.

Douglas A. Arenberg, S L Kunkel, Peter J. Polverini(University of Michigan–Ann Arbor), Mary Glass(Michigan Medicine), M D Burdick(Michigan Medicine), Robert M. Strieter(Michigan Medicine)
Journal of Clinical Investigation
June 15, 1996
Cited by 401Open Access
Full Text

Abstract

The salient feature of solid tumor growth is the strict dependence on local angiogenesis. We have previously demonstrated that IL-8 is an angiogenic factor present in freshly isolated specimens of human non-small cell lung cancer (NSCLC). Using a model of human NSCLC tumorigenesis in SCID mice, we now report that IL-8 acts as a promoter of human NSCLC tumor growth through its angiogenic properties. Passive immunization with neutralizing antibodies to IL-8 resulted in more than 40% reduction in tumor size and was associated with a decline in tumor-associated vascular density and angiogenic activity. IL-8 did not act as an autocrine growth factor for NSCLC proliferation. The reduction in primary tumor size in response to neutralizing antibodies to IL-8 was also accompanied by a trend toward a decrease in spontaneous metastasis to the lung. These data support the notion that IL-8 plays a significant role in mediating angiogenic activity during tumorigenesis of human NSCLC, thereby offering a potential target for immunotherapy against solid tumors.


Related Papers

No related papers found

Powered by citation graph analysis